Pacer Advisors Inc. Has $4.39 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Pacer Advisors Inc. lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 76.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,890 shares of the company’s stock after purchasing an additional 13,782 shares during the period. Pacer Advisors Inc.’s holdings in Neurocrine Biosciences were worth $4,390,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Vestal Point Capital LP acquired a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $105,408,000. Norges Bank bought a new position in Neurocrine Biosciences in the 4th quarter worth $35,731,000. Vanguard Group Inc. lifted its position in Neurocrine Biosciences by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after acquiring an additional 220,598 shares during the last quarter. Iron Triangle Partners LP bought a new stake in Neurocrine Biosciences during the first quarter valued at about $30,342,000. Finally, Renaissance Technologies LLC grew its position in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock valued at $339,790,000 after purchasing an additional 216,500 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Trading Down 1.1 %

NASDAQ:NBIX opened at $116.49 on Wednesday. The stock has a market capitalization of $11.72 billion, a P/E ratio of 32.09 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 1 year low of $103.63 and a 1 year high of $157.98. The firm has a 50 day moving average of $137.27 and a 200-day moving average of $137.93.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.95 EPS. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NBIX shares. Barclays cut their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Jefferies Financial Group increased their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a research note on Thursday, August 29th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Finally, Morgan Stanley raised their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $162.20.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Julie Cooke sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the completion of the sale, the insider now owns 18,202 shares in the company, valued at approximately $2,551,738.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Julie Cooke sold 10,000 shares of Neurocrine Biosciences stock in a transaction on Monday, July 1st. The stock was sold at an average price of $140.19, for a total value of $1,401,900.00. Following the completion of the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,551,738.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary A. Lyons sold 930 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total value of $139,527.90. Following the transaction, the director now directly owns 119,047 shares in the company, valued at approximately $17,860,621.41. The disclosure for this sale can be found here. Insiders have sold a total of 71,798 shares of company stock worth $10,676,096 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.